Literature DB >> 9190921

Functional in vivo MHC class II loading by endogenously synthesized glycoprotein during viral infection.

A Oxenius1, M F Bachmann, D Mathis, C Benoist, R M Zinkernagel, H Hengartner.   

Abstract

MHC class II presentation of antigenic peptides derived from soluble proteins is usually preceded by antigenic uptake via (nonreceptor-mediated) endocytosis by professional APCs, followed by processing in endosomal compartments. Although in vitro alternative pathways for MHC class II loading have been described for certain intracellularly synthesized proteins, the importance of these pathways has not been assessed in vivo. We have shown previously that endogenously produced membrane-associated glycoprotein (GP) of lymphocytic choriomeningitis virus (LCMV), a noncytopathic virus, can be presented in vitro on MHC class II molecules in the absence of the invariant chain (Ii), whereas the cytosolic LCMV nucleoprotein (LCMV-NP) failed to be presented under the same conditions. Taking advantage of this system, we analyzed presentation of LCMV-GP and LCMV-NP in vivo in Ii-deficient mice and followed the induced Th cell and B cell responses. At early time points after LCMV infection of li-deficient mice, we found in vivo MHC class II loading exclusively by the endogenously synthesized LCMV-GP, whereas no MHC class II loading by LCMV-NP could be detected. As a direct consequence, LCMV-specific Th cells exhibited initially only LCMV-GP specificity. In contrast, both LCMV-GP- and LCMV-NP-derived epitopes were presented in comparable amounts on APCs upon LCMV infection of normal mice, and LCMV-GP- as well as LCMV-NP-specific Th cells were comparably induced in vivo. Thus, cell internal MHC class II loading pathways are functional in vivo and may become dominant if the usual Ag presentation pathways are hampered.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9190921

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Induction of antiviral antibodies by DNA immunization requires neither perforin-mediated nor CD8(+)-T-cell-mediated lysis of antigen-expressing cells.

Authors:  D E Hassett; J Zhang; J L Whitton
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

Review 2.  Coverage of related pathogenic species by multivalent and cross-protective vaccine design: arenaviruses as a model system.

Authors:  Jason Botten; John Sidney; Bianca R Mothé; Bjoern Peters; Alessandro Sette; Maya F Kotturi
Journal:  Microbiol Mol Biol Rev       Date:  2010-06       Impact factor: 11.056

Review 3.  Presentation of cytosolic antigens via MHC class II molecules.

Authors:  Delu Zhou; Janice S Blum
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

4.  Cutting edge: murine CD59a modulates antiviral CD4+ T cell activity in a complement-independent manner.

Authors:  M Paula Longhi; Baalasubramanian Sivasankar; Nader Omidvar; B Paul Morgan; Awen Gallimore
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

5.  The microRNA miR-182 is induced by IL-2 and promotes clonal expansion of activated helper T lymphocytes.

Authors:  Anna-Barbara Stittrich; Claudia Haftmann; Evridiki Sgouroudis; Anja Andrea Kühl; Ahmed Nabil Hegazy; Isabel Panse; Rene Riedel; Michael Flossdorf; Jun Dong; Franziska Fuhrmann; Gitta Anne Heinz; Zhuo Fang; Na Li; Ute Bissels; Farahnaz Hatam; Angelina Jahn; Ben Hammoud; Mareen Matz; Felix-Michael Schulze; Ria Baumgrass; Andreas Bosio; Hans-Joachim Mollenkopf; Joachim Grün; Andreas Thiel; Wei Chen; Thomas Höfer; Christoph Loddenkemper; Max Löhning; Hyun-Dong Chang; Nikolaus Rajewsky; Andreas Radbruch; Mir-Farzin Mashreghi
Journal:  Nat Immunol       Date:  2010-10-10       Impact factor: 25.606

6.  MyD88 intrinsically regulates CD4 T-cell responses.

Authors:  Shenghua Zhou; Evelyn A Kurt-Jones; Anna M Cerny; Melvin Chan; Roderick Terry Bronson; Robert W Finberg
Journal:  J Virol       Date:  2008-12-03       Impact factor: 5.103

7.  Association of HLA antigens and BCR-ABL transcripts in leukemia patients with the Philadelphia chromosome.

Authors:  Daiana Landenberger de Carvalho; Cristian Dias Barbosa; André Luiz de Carvalho; Sandra Trevisan Beck
Journal:  Rev Bras Hematol Hemoter       Date:  2012

8.  Antagonistic variant virus prevents wild-type virus-induced lethal immunopathology.

Authors:  Lukas Hunziker; Mike Recher; Adrian Ciurea; Marianne M A Martinic; Bernhard Odermatt; Hans Hengartner; Rolf M Zinkernagel
Journal:  J Exp Med       Date:  2002-10-21       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.